253772-38-2

Upstream product

• 253772-35-9 4-bromo-2-ethyl-1-(1-methylbutyl)imidazole-5-carboxaldehyde ethylene glycol acetal 
• 253772-32-6 4-bromo-2-ethyl-1-(1-methylbutyl)imidazole-5-carboxaldehyde 
• 4002-82-8 4,5-dibromo-2-ethyl-1H-imidazole 
• 1072-62-4 2-Ethylimidazole 
• 279694-20-1 (2,4-dichloro-phenyl)-[5-[1,3]dioxolan-2-yl-2-ethyl-1-(1-methyl-butyl)-1H-imidazol-4-yl]-methanone 
• 253772-31-5 4,5-dibromo-2-ethyl-1-(1-methylbutyl)imidazole 

Downstream Products

• 253772-41-7 methyl 4-(2,4-dichlorobenzoyl)-2-ethyl-1-(1-methylbutyl)imidazole-5-carboxylate 

Relevant academic research and scientific papers

Synthesis of 6-substituted imidazo[4,5-d]pyridazin-7-ones

A novel synthesis of 6-substituted imidazo[4,5-d]pyridazin-7-ones is described, which employs 1,2-disubstituted 4-aroylimidazole-5-carboxylates as key intermediates.

Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists

The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: wherein A and B can be C or N and D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.